1.Mechanism of Ⅲ in the treatment of proteinuria in chronic kidney disease: a network pharmacology-based study.
Huaxi LIU ; Zhihao LÜ ; Chunyang TIAN ; Wenkun OUYANG ; Yifan XIONG ; Yanting YOU ; Liqian CHEN ; Yijian DENG ; Xiaoshan ZHAO ; Xiaomin SUN
Journal of Southern Medical University 2019;39(2):227-234
OBJECTIVE:
To identify the main active components in Ⅲ and their targets and explore the mechanism by which Ⅲ alleviates proteinuria in chronic kidney disease (CKD) based on network pharmacology.
METHODS:
The active components of Ⅲ and their potential targets, along with the oral bioavailability and drug-like properties of each component were searched in the TCMSP database. The proteinuria-related targets were searched in the GeneCards database. The active component-target network was constructed using Cytoscape software, and the acquired information of the targets from ClueGO was used for enrichment analysis of the gene pathways.
RESULTS:
A total of 102 active components were identified from Ⅲ. These active components acted on 126 targets, among which 69 were related to proteinuria. Enrichment analysis revealed fluid shear stress- and atherosclerosisrelated pathways as the highly significant pathways in proteinuria associated with CKD.
CONCLUSIONS
We preliminarily validated the prescription of Ⅲ and obtained scientific evidence that supported its use for treatment of proteinuria in CKD. The findings in this study provide a theoretical basis for further study of the mechanism of Ⅲ in the treatment of proteinuria in CKD.
Biological Availability
;
Drugs, Chinese Herbal
;
chemistry
;
pharmacokinetics
;
therapeutic use
;
Humans
;
Proteinuria
;
drug therapy
;
etiology
;
metabolism
;
Renal Insufficiency, Chronic
;
complications
;
metabolism